FDA advisors recommend AstraZeneca, Sanofi antibody to protect babies from RSVIf the Food and Drug Administration approves nirsevimab, it will be the first medical intervention available in the U.S. that can protect infants from RSV.[Collection]

If the Food and Drug Administration approves nirsevimab, it will be the first medical intervention available in the U.S. that can protect infants from RSV.https://www.cnbc.com/2023/06/08/fda-advisors-recommend-astrazeneca-antibody-for-infants-for-rsv.html